InxMed (Shanghai) Co., Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS8
PHASE 3 / 2-31
RECRUITING2
READOUTS ≤12 MONTHS1
READOUT SLIPPED >6 MO57%
Delay Index: of 7 active trials registered more than a year ago, 4 have moved their primary completion (readout) date by more than 6 months since first registration (median +9.9 months). See all sponsors →
Open InxMed (Shanghai) Co., Ltd. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| IN10018 NCT05994131 |
P1/2 | Active, not recruiting | NSCLC | 110 | 2025-09-20 (-10 mo) |
| IN10018 NCT05827796 |
P1/2 | Active, not recruiting | Pancreatic Cancer | 70 | 2025-10-11 (-2 mo) |
| IN10018 NCT06030258 |
P1/2 | Active, not recruiting | Small Cell Lung Cancer Extensive Stage | 120 | 2025-11-20 (+10 mo) |
| IN10018 in combination with PLD NCT05551507 |
P1/2 | Active, not recruiting | Platinum-resistant Ovarian Cancer | 150 | 2026-05-11 (+23 mo) |
| IN10018 NCT06014528 |
P2 | Active, not recruiting | Ovarian Cancer Recurrent | 168 | 2027-03-24 (+28 mo) |
| D1553 NCT06166836 |
P1/2 | Active, not recruiting | Solid Tumor | 140 | 2027-12-31 (+24 mo) |
| IN10018 in combination with D-1553 NCT07174908 |
P3 | Recruiting | Non-Small Cell Lung Cancer | 400 | 2028-09 |
| IN10018 in combination with RNK08954 NCT07441174 |
P1/2 | Recruiting | Solid Tumor Cancer; PDAC | 92 | 2031-02-28 |